3 Reasons You Should Buy the Coronavirus Vaccine Dip in Peloton
With the great news of progress on two different COVID-19 vaccine candidates, many stocks that have benefited from the work-from-home trend were crushed. Peloton (NASDAQ: PTON) was one of the bigger victims, with its shares down a whopping 20% after Pfizer and BioNTech announced 90% effectiveness on their version earlier this month.
But Peloton is so much more than simply a business that's benefited from people spending more time at home. Here's why investors should buy the vaccine news dip.
Peloton has been painted with that broad brush because it is clearly benefiting this year from a surge in demand due to COVID-19. For example, before COVID-19, the time from when a customer would order a Peloton bike to when it would be delivered was roughly two weeks. But over this summer it surged to 10 to 12 weeks in some, if not most, markets. Peloton has been selling every bike it can produce.
Source Fool.com
